Tada, I think any news that enhances the long term commercial viability of RVX will transcend any shorter term market impact of the cononavirus.  The market was probably due for a correction anyway and the virus likely contributed to that effect.

Sometimes I do get a bit impatient with RVX and that no doubt comes out in the odd post.  I guess we all need to vent once in awhile.  But yes, things like a completed P3 trial that has uncovered some diamonds in the rough, a BTD from the FDA and a team committed to marketing the science in an accepted academic way goes a long way to enhancing the company's financial opportunities and credibility.  You certainly can't accuse them of being opportunistic short term stock pumpers.

I confess to having been too lazy to properly delinate the difference between statins and SGLT2s but probably figured that someone out there would point that out anyway.  In the future I will endeavor to be less cavalier about those kinds of statements.

Like most on this board I look forward to seeing what comes out of next month's conference, and any other releases the company might have either before or shortly afterward that might enhance the company's fortunes.